Cited by 900SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAnimal Virus Infections Studies

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Open access
Hou, Yixuan J., Chiba, Shiho, Halfmann, Peter, Ehre, Camille, Kuroda, Makoto, Dinnon, Kenneth H., Leist, Sarah R., Schäfer, Alexandra +18 more·2020·Science

Published version of a preprint

Abstract

Changing with the times: Pandemic spread of a virus in naïe populations can select for mutations that alter pathogenesis, virulence, and/or transmissibility. The ancestral form of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged from China has now been largely replaced by strains containing the mutation D614G (Asp 614 -to-Gly) in the viral spike protein. Hou et al. compared the characteristics of the new variant against the ancestral form in a series of experiments in human cells and animal models. The variant is better at infecting upper-airway epithelial cells and replicates in greater numbers than the ancestral virus. Evidence indicates modest, if any, significant changes to virulence in animal models. Therefore, the virus appears to have evolved for greater transmissibility in humans rather than for greater pathogenicity. The mutation renders the new virus variant more susceptible to neutralizing antisera without altering the efficacy of vaccine candidates currently under development. Science , this issue p. 1464

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/science.abe8499

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hou, Y. J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K. H., Leist, S. R., Schäfer, A., Nakajima, N., Takahashi, K., Lee, R. E., Mascenik, T. M., Graham, R., Edwards, C. E., Tse, L. V., Okuda, K., Markmann, A. J., Bartelt, L., de Silva, A., Margolis, D. M., Boucher, R. C., Randell, S. H., Suzuki, T., Gralinski, L. E., Kawaoka, Y., & Baric, R. S.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • University of Wisconsin–Madison (US)
  • Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • National Institute of Infectious Diseases (JP)
  • Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Corresponding author
  • Hou, Yixuan J.
  • Chiba, Shiho
  • Kawaoka, Yoshihiro
  • Baric, Ralph S.
Venue
Science
Published
2020-12-18
Volume
370
Issue
6523
Pages
1464-1468
ISSN
  • 0036-8075 (ISSN-L)
  • 1095-9203
OpenAlex
W3101992496
Cited by
900
References
35
Citations by year
2026: 11 · 2025: 46 · 2024: 66 · 2023: 105 · 2022: 228 · 2021: 413 · 2020: 30
FWCI
25.46
Type
journal article
Language
en
Open access
Locations
  • Science (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by-nc-nd)
  • ImmPort
Funders
  • National Institutes of Health (AI110700, AI151797, AI069274, HHSN272201400008C, HHSN272201700036I, CA260543, UM1-AI126619)
  • Japan Agency for Medical Research and Development (JP20fk0108104, JP19fk0108110, JP19fk0108113, JP19fm0108006)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords
SARS-CoV-2, D614G mutation, spike protein, virus transmission, competitive fitness, viral replication, airway epithelial cells, ACE2 transgenic mice, golden hamster, viral pathogenesis, neutralizing antibodies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review